Symptomatic myopathies in sarcoidosis: disease spectrum and Myxovirus resistance protein A (MxA) expression.
Sign Up to like & getrecommendations! Published in 2022 at "Rheumatology"
DOI: 10.1093/rheumatology/keac668
Abstract: OBJECTIVES Symptomatic myopathy in sarcoidosis patients is not always due to sarcoid myopathy (SM). We investigated the clinical and pathological spectrum including myxovirus resistance protein A (MxA) expression among sarcoidosis patients. METHODS We reviewed the… read more here.
Keywords: sarcoidosis; mxa expression; myxovirus resistance; sarcoidosis patients ... See more keywords
Author update: Sarcoplasmic MxA expression: A valuable marker of dermatomyositis
Sign Up to like & getrecommendations! Published in 2017 at "Neurology"
DOI: 10.1212/wnl.0000000000004102
Abstract: Soon after our article published,1 we learned the sale of the myxovirus resistance A (MxA) polyclonal antibodies used in the study (Mx1/2/3 [H-285], sc-50509, Santa Cruz Biotechnology, Dallas, TX) had been discontinued. Furthermore, we received… read more here.
Keywords: sarcoplasmic mxa; mxa; mxa expression; dermatomyositis ... See more keywords
Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients Receiving Heat Shock Protein Peptide Complex 96 Vaccination
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.865779
Abstract: Heat shock protein peptide complex 96 (HSPPC-96) has been proven to be a safe and preliminarily effective therapeutic vaccine in treating newly diagnosed glioblastoma multiforme (GBM) (NCT02122822). However, the clinical outcomes were highly variable, rendering… read more here.
Keywords: vaccination; expression; low mxa; mxa expression ... See more keywords